NCT07593573Active, not recruiting
the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
A Clinical Study on the Exploration of MTAP Deletion in Osteosarcoma Specimens by Immunohistochemistry
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
MTAP deletion frequently occurs in osteosarcoma, and PRMT5 has been identified as a synthetic lethal target for cancers with homozygous deletion of the MTAP gene, making it a promising target for anti-tumor drug development.This study aims to evaluate the overall status of MTAP deficiency in the tissues of osteosarcoma patients and its correlation with clinical features such as metastasis and immune subtypes by examining the MTAP protein expression levels in previous histological samples of the patients and combining this with their clinicopathological data.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 12 May 2026
- Start date
- 15 Dec 2025
- Primary completion date
- 15 Jun 2026
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT07593573
What you commit to
- Study type: Observational
- Planned participants: 100
- From 15 Dec 2025 to the primary completion date, 15 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- those who had been previously treated with antiangiogenic TKIs and single IE chemotherapy;
- all patients were assessed by the sarcoma board including a thoracic surgeon with at least 10 years surgical experience. Patients with lung metastases only were carefully assessed for eligibility for metastasectomy, of whom those who were suitable for surgery were excluded from this study;
- surgical procedure or radiotherapy within 4 weeks of enrollment;
- activegastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation;
Other illness
- weight loss of 20% or more before illness;
- women who were pregnant or breast feeding, other malignancy;
- positive HBV/HCV/HIV serology, and known allergy to the experimental agents.
Lab values
- those who had severe or uncontrolled medical disorders that could jeopardize the outcomes of the study. These confounding conditions included, cardiac clinical symptoms or disease with left ventricular ejection fraction\<50%, and hypertension that could not be well controlled with antihypertensive drugs.;
- proteinuria or hematuria, denutrition with albuminemia \<25 g/L;
Other
- brain or leptomeningeal metastasis;
Who the study is looking for
- advanced recurrent and refractory osteosarcoma confirmed by histopathology;
- initial treatment in the Orthopedic/Oncology Departments of Peking University People's Hospital or Peking University Shougang Hospital;
- progression less than 6 months after first-line chemotherapy with a combination of high-dose methotrexate, doxorubicin, cisplatin and ifosfamide (first-line chemotherapy);
- measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST 1.1) ;
- Eastern Cooperative Oncology Group performance status ≤ 1 ;
- acceptable haematologic, hepatic, and renal function.
Age in the registry: 12 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.